Rationale and design of RE - LY : randomized evaluation of long - term anticoagulant therapy , warfarin , compared with dabigatran . 
<br>
<br> Vitamin K antagonists ( VKAs ) are effective for stroke prevention in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">atrial_2</font> <font color="red">fibrillation_2</font> <font color="red">(_2</font> <font color="red">AF_2</font> <font color="red">)_2</font> but are difficult to use . Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran . It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin ( international normalized ratio 2 - 3 ) in the RE - LY trial . Two doses of dabigatran ( 110 and 150 mg BID ) are being evaluated . RE - LY is a phase 3 , prospective , randomized , open - label <font color="red">multinational_2</font> <font color="red">(_2</font> <font color="red">44_2</font> <font color="red">countries_2</font> <font color="red">)_2</font> <font color="red">trial_2</font> <font color="red">of_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">nonvalvular_2</font> <font color="red">AF_2</font> <font color="red">and_2</font> <font color="red">at_2</font> <font color="red">least_2</font> <font color="red">1_2</font> <font color="red">risk_2</font> <font color="red">factor_2</font> <font color="red">for_2</font> <font color="red">stroke_2</font> <font color="red">._2</font> <font color="red">Recruitment_1</font> <font color="red">concluded_1</font> <font color="red">with_1</font> <font color="red">a_1</font> <font color="red">total_1</font> <font color="red">of_1</font> <font color="red">18,113_2</font> <font color="red">patients_2</font> <font color="red">._2</font> <font color="red">Patients_2</font> <font color="red">who_2</font> <font color="red">were_2</font> <font color="red">VKA_2</font> <font color="red">-_2</font> <font color="red">naive_2</font> <font color="red">and_2</font> <font color="red">experienced_2</font> <font color="red">are_2</font> <font color="red">included_2</font> <font color="red">in_2</font> <font color="red">balanced_2</font> <font color="red">proportions_2</font> <font color="red">._2</font> The primary outcome is stroke ( including hemorrhagic ) or systemic embolism . Safety outcomes are bleeding , liver function abnormalities , and other adverse events . Adjudication of end points is blinded to drug assignment . The trial is expected to accrue a minimum of 450 events with a minimum 1-year of follow - up . RE - LY is the largest AF stroke prevention trial yet undertaken . It is unique because it includes <font color="red">equal_1</font> <font color="red">numbers_1</font> <font color="red">of_1</font> <font color="red">VKA_1</font> <font color="red">-_1</font> <font color="red">experienced_1</font> <font color="red">and_1</font> <font color="red">naive_1</font> <font color="red">patients_1</font> and evaluates 2 different dosages of dabigatran , which may allow tailoring of dosing to individual patient needs . The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial . Results are expected in 2009 .